Lipocine Inc (LPCN)

Currency in USD
3.1800
+0.0100(+0.32%)
Real-time Data·
LPCN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
LPCN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.14003.2400
52 wk Range
2.68387.1800
Key Statistics
Prev. Close
3.17
Open
3.14
Day's Range
3.14-3.24
52 wk Range
2.6838-7.18
Volume
40.25K
Average Volume (3m)
50.73K
1-Year Change
-50.31%
Book Value / Share
3.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LPCN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.3750
Upside
+131.92%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Lipocine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell

Lipocine Inc Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Compare LPCN to Peers and Sector

Metrics to compare
LPCN
Peers
Sector
Relationship
P/E Ratio
−3.2x−2.5x−0.5x
PEG Ratio
−0.080.000.00
Price/Book
0.9x0.7x2.6x
Price / LTM Sales
4.7x1.6x3.2x
Upside (Analyst Target)
132.6%167.7%43.8%
Fair Value Upside
Unlock16.1%5.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.3750
(+131.92% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.35 / --
Revenue / Forecast
93.86K / 1.50M
EPS Revisions
Last 90 days

LPCN Income Statement

People Also Watch

11.080
UMAC
-6.50%
15.320
NUWE
-2.79%
1.2950
CETX
-4.07%
2.06
NMRA
+20.47%
2.845
OKYO
-1.91%

FAQ

What Stock Exchange Does Lipocine Trade On?

Lipocine is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Lipocine?

The stock symbol for Lipocine is "LPCN."

What Is the Lipocine Market Cap?

As of today, Lipocine market cap is 17.01M.

What Is Lipocine's Earnings Per Share (TTM)?

The Lipocine EPS (TTM) is -1.00.

From a Technical Analysis Perspective, Is LPCN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Lipocine Stock Split?

Lipocine has split 2 times.

How Many Employees Does Lipocine Have?

Lipocine has 16 employees.

What is the current trading status of Lipocine (LPCN)?

As of 18 Jul 2025, Lipocine (LPCN) is trading at a price of 3.18, with a previous close of 3.17. The stock has fluctuated within a day range of 3.14 to 3.24, while its 52-week range spans from 2.68 to 7.18.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.